期刊文献+

艾地苯醌联合多巴丝肼治疗帕金森病的疗效及对氧化应激因子的影响 被引量:24

Efficacy observation of idebenone combined with levodopaand its effect on oxidative stress level in patients with Parkinson′s disease
下载PDF
导出
摘要 目的探讨艾地苯醌联合多巴丝肼治疗帕金森病(PD)的疗效及对PD患者氧化应激水平的影响。方法初次于我科住院治疗的临床确诊的PD患者50例,随机数字表法分成观察组(25例)及对照组(25例)。观察组:多巴丝肼+艾地苯醌治疗;对照组:常规多巴丝肼治疗;入院第2天(治疗前)、治疗14d(治疗后)分别对2组患者记录以下指标:①统一PD评分量表(UPDRS评分)、Hoehn-Yahr分级;②测定氧化应激反应指标:超氧化物歧化酶(SOD)、8-羟基脱氧鸟苷酸(8-OHdG)、丙二醛(MDA)的含量。结果 2组治疗后UPDRS评分均降低,且观察组低于对照组(P<0.05);与对照组比较,观察组治疗后SOD水平均升高,8-OHdG、MDA水平降低。结论艾地苯醌联合多巴丝肼治疗可有效改善PD患者临床症状,增强抗氧化活性。 Objective To explore the clinical efficacy of idebenone combined with levodopa in patients with Parkinson′s disease,and its effect on oxidative stress level in patients with Parkinson′s disease. Methods Fifty patients with Parkinson′s disease were randomly divided into two groups: the test group (25 cases) and the control group(25cases). The two groups were given levodopa. The test group was added with idebenone. The Unified Parkinson′s Disease Rating Scale (UPDRS), H-Y stage, SOD, 8-OHdG and MDA were compared and analyzed before and after treatment in two groups. Results After treatment,the UPDRS of two groups were decreased. The UPDRS of test group were obviously lower than that of the control group, the difference was statistically significant (P <0.05). Compared with the control group, the SOD level in the test group increased, the levels of 8-OHdG and MDA decreased after treatment. Conclusion Idebenone combined with levodopa can effectively improve clinical symptoms, enhance antioxidant activity in patients with PD.
作者 康蓓 慕生枝 李妮妮 郭荷娜 Kang Bei;Mu Shengzhi;Li Nini;Guo Hena(epartment of Neurology, Shaanxi People's Hospital, Xi'an 710068, China)
出处 《山西医药杂志》 CAS 2019年第16期1958-1960,共3页 Shanxi Medical Journal
关键词 艾地苯醌 帕金森病 氧化性应激 Idebenone Parkinson disease Oxidative stress
  • 相关文献

参考文献2

二级参考文献29

  • 1张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:616
  • 2王新德,陈生弟.神经病学[M].北京:人民军医出版社,2006.
  • 3Goetz CG,Pappert EJ.Textbook of clinical neurology[M].Philadelphia:W B saunders company,1999:223.
  • 4Jankovic J,Tolosa E.Parkinson's disease and movement disorders[M].3rd ed.New York:Lippincott williams & wilkins,1998:56-59.
  • 5陈生弟.神经病学[M].北京:科学出版社,2004:101-107.
  • 6Maurice V,Allan H.Principles of Neurology[M].7th ed.New York:McGraw- Hill,2001:101.
  • 7Rowland LP.Merritt' s Neurology[M]. 10th ed.New York:Lippincott williams & wilkins,2000:44.
  • 8Victor M,Ropper AH.Adams and victor's principles of neurology[M].7th ed.New York:McGraw-Hill,2001:11 - 16.
  • 9Zhang ZX, Roman GC, Hong Z,et al. Parkinson's disease inChina: prevalence in Beijing, Xian, and Shanghai[ J]. Lancet,2005,365(9459): 595-597.
  • 10Postuma RB, Berg D, Stem M, et al. MDS clinical diagnosticcriteria for Parkinson、disease[ J]. Mov Disord, 2015,30( 12):1591-1601. DOI: 10.1002/mds.26424.

共引文献1195

同被引文献194

引证文献24

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部